|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of ustekinumab,a human interleukin-12/23 monoclonal antibody,in patients with psoriasis:76-week result from randomized,double-blind,Placebo-controlled trial显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 2 | Effects of increasing atmospheric on COs vegetation显示文摘 | Kimball B A Manu EY J R NA KA Yama F S | 1993 | Vegetatio1993，，104105： | 1 |
| 3 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in pa- tients with psoriasis: 76-week results fi'om a randomised, dou- ble-blind, placebo-controlled trial (PHOENIX 1)显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 4 | Efficacy and safety of ustekinumab,a human interleukin-12/23 mono- clonal antibody,in patients with psoriasis: 76-week resuhs from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1 ) 显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 5 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:76-week results from s randomized, double-blind, placebo-controlled trial (PHOENIX1) 显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 6 | Improved communications and hearing protection in helmet systems : The communications earplug 显示文摘 | Powell JA Kimball KA Mozo BT | 2003 | Mil Med2003，168，6： | 1 |
| 7 | Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study显示文摘 | Kimball AB Papp KA Wasfi Y | 2013 | J Eur Acad Dermatol Venereol2013，27，12： | 1 |
| 8 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis :76-week results from a randomised, double- blind, placebo-controlled trial ( PHOENIX 1 ) 显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 9 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week resuits from a randomised, double-blind, placebo-controlled trial 显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 10 | Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study 显示文摘 | Kimball AB Papp KA Wasfi Y | 2013 | J Eur Acad Dermatol Venereol2013，27，12： | 1 |
| 11 | Efficacy and safety of ustekinnmab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1 )显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 12 | Efficacy and safety of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1 ) 显示文摘 | Leonardi CL Kimball AB Papp KA | 2008 | Lancet2008，371，9625： | 1 |
| 13 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doulde-blind, placebo-controlled trial (PHOENIX 1 ) 显示文摘 | LEONARDI CL KIMBALL AB PAPP KA | 2008 | Lancet2008，371，9625： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员